This independent medical education meeting has been funded by Astellas.

The latest findings from the EV-103 study add support for the first-line use of enfortumab vedotin plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Individuals with urothelial bladder cancer have a distinct urinary volatile organic compound profile that could potentially be used as a biomarker for diagnosis and surveillance, UK research suggests.

The Meet-URO12 trial of maintenance niraparib in advanced urothelial cancer patients without progression after first-line chemotherapy has failed to meet its primary endpoint of improvement in progression-free survival.

Treatment with immune checkpoint inhibitors may improve the overall survival of people with metastatic small-cell urothelial cancer, suggests a chart review.

Arjun Balar talks through the INDUCE-1 trial findings for patients with advanced urothelial carcinoma who were given the ICOS agonist feladilimab alone or alongside pembrolizuamb. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Updated results from the phase 3 IMvigor211 trial indicate that some patients with advanced urothelial cancer may derive a long-term benefit from atezolizumab after progression on platinum-based chemotherapy.

medwireNews: Sacituzumab govitecan has been given accelerated approval from the US FDA for previously treated locally advanced or metastatic urothelial cancer.

Shilpa Gupta and Petros Grivas share their thoughts on the key practicing-changing trials in metastatic urothelial cancer, including EV-301, EV-201, TITAN-TCC, and TROPiCS-04 (16:47).

Petros Grivas and Shilpa Gupta discuss the key abstracts in the nonmetastatic urothelial cancer setting, sharing their thoughts on how the data inform clinical practice (10:39).

Thomas Powles outlines the primary results of the phase 3 EV-301 trial comparing enfortumab vedotin with chemotherapy in patients who have received prior treatment for locally advanced or metastatic urothelial carcinoma (4:37).

Results from the phase 3 CheckMate 274 trial support the adjuvant use of nivolumab in patients with muscle-invasive urothelial carcinoma at high risk for recurrence after surgery.

Genomic alterations in CDKN2A are associated with worse clinical outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors, report US researchers.

Thomas Powles outlines the DANUBE trial pitting durvalumab, with or without tremelimumab, against chemotherapy in the metastatic urothelial cancer setting. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Yohann Loriot discusses the TROPHY-U-01 trial update confirming that sacituzumab govitecan is active in heavily pretreated metastatic urothelial cancer. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Chinese researchers have developed a noninvasive test for urothelial cancer, based on low-coverage whole-genome sequencing, that has better sensitivity and comparable specificity to that of cytology.

Ajjai Alva discusses the negative KEYNOTE-361 trial findings for pembrolizumab with or without chemotherapy for treatment-naïve advanced urothelial cancer. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Enrique Grande tells us why the IMvigor130 data, although very promising, are not quite ready for translation to the clinic yet (1:43).

The JAVELIN Bladder 100 trial has shown a significant improvement in the overall survival of advanced urothelial cancer patients with the addition of avelumab to best supportive care in the maintenance setting.